



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, June 23, 2026

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

Pharma Mar, S.A. announces that Merck has submitted a marketing application to Japan's Ministry of Health, Labour and Welfare (MHLW) for Zepzelca® (lurbinectedin) regarding the first line maintenance treatment of small cell lung cancer (SCLC). Merck's New Drug Application (NDA) was granted priority review.

Please find attached press release that Pharma Mar, S.A. will distribute to the media.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com

PharmaMar's partner, Merck, has submitted a New Drug Application in Japan for Zepzelca® (lurbinectedin) regarding first line maintenance therapy in small cell lung cancer

Madrid, June 23rd, 2026.- PharmaMar (MSE: PHM), has announced that Merck (MRK.DE) has submitted a marketing application to Japan's Ministry of Health, Labour and Welfare (MHLW) for Zepzelca® (lurbinectedin) regarding the first line maintenance treatment of small cell lung cancer (SCLC). Merck's New Drug Application (NDA) was granted priority review.

In April 2025, PharmaMar and Merck announced an exclusive licensing agreement for the development and commercialization in Japan of lurbinectedin for the treatment of SCLC.

In addition, on March 19th, 2026, Japan's MHLW designated lurbinectedin as an orphan drug, a category granted to drugs intended for the treatment of diseases affecting fewer than 50,000 patients and for which there is a particularly high unmet medical need.

Lurbinectedin in combination with atezolizumab has already been approved in Europe and in 14 other countries, including the United States, for first-line maintenance treatment of this disease.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself. In addition, Zepzelca® (lurbinectedin), in the US and other countries; and Aplidin® (plitidepsin), in Australia, each with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: PM534 and PM54.

Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi) and contract-manufacturing (CDMO) of oligonucleotides. For more information, please visit: www.pharmamar.com.

About Zepzelca®

Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinascidia turbinata. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:

Lara Vadillo – Communications director lvadillo@pharmamar.com

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– VP Capital Markets & Investor Relations

Natalia Amo – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at www.pharmamar.com